This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Jul 24;359(4):420-2.

doi: 10.1056/NEJMe0802241.

Sorafenib in liver cancer--just the beginning

Lewis R Roberts

PMID: 18650519
DOI: 10.1056/NEJMe0802241

Editorial

Sorafenib in liver cancer--just the beginning

Lewis R Roberts. N Engl J Med. 2008.

. 2008 Jul 24;359(4):420-2.

doi: 10.1056/NEJMe0802241.

Author

Lewis R Roberts

PMID: 18650519
DOI: 10.1056/NEJMe0802241

No abstract available

PubMed Disclaimer

Comment in

Sorafenib in advanced hepatocellular carcinoma.
Spinzi G, Paggi S. Spinzi G, et al. N Engl J Med. 2008 Dec 4;359(23):2497-8; author reply 2498-9. doi: 10.1056/NEJMc081780. N Engl J Med. 2008. PMID: 19052134 No abstract available.
Sorafenib in advanced hepatocellular carcinoma.
Copur MS. Copur MS. N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9. N Engl J Med. 2008. PMID: 19065701 No abstract available.
Sorafenib in advanced hepatocellular carcinoma.
Palmer DH. Palmer DH. N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9. N Engl J Med. 2008. PMID: 19065750 No abstract available.

Comment on

Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Clinical Trial.

Similar articles

[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M. Reig M, et al. Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18. Gastroenterol Hepatol. 2010. PMID: 20851505 Spanish. No abstract available.
Sorafenib in advanced hepatocellular carcinoma.
Palmer DH. Palmer DH. N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9. N Engl J Med. 2008. PMID: 19065750 No abstract available.
Sorafenib in advanced hepatocellular carcinoma.
Copur MS. Copur MS. N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9. N Engl J Med. 2008. PMID: 19065701 No abstract available.
Sorafenib in hepatocellular carcinoma.
Josephs DH, Ross PJ. Josephs DH, et al. Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
Sorafenib.
Rini BI. Rini BI. Expert Opin Pharmacother. 2006 Mar;7(4):453-61. doi: 10.1517/14656566.7.4.453. Expert Opin Pharmacother. 2006. PMID: 16503817 Review.

See all similar articles

Cited by

Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D, Sun FF, Wang D, Wang T, Peng JJ, Feng JQ, Li H, Wang C, Zhou DJ, Luo H, Fu ZQ, Zhang T. Li D, et al. Oncol Res. 2020 Dec 10;28(5):467-481. doi: 10.3727/096504020X15925659763817. Epub 2020 Jun 19. Oncol Res. 2020. PMID: 32560747 Free PMC article.
Novel roles of Vmp1: inhibition metastasis and proliferation of hepatocellular carcinoma.
Guo L, Yang LY, Fan C, Chen GD, Wu F. Guo L, et al. Cancer Sci. 2012 Dec;103(12):2110-9. doi: 10.1111/cas.12025. Epub 2012 Oct 30. Cancer Sci. 2012. PMID: 22971212 Free PMC article.
The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma.
Yuan L, Zhao H, Zhang L, Liu X. Yuan L, et al. Tumour Biol. 2013 Oct;34(5):3027-34. doi: 10.1007/s13277-013-0867-z. Epub 2013 Aug 2. Tumour Biol. 2013. PMID: 23907578
Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status.
Sarpel U, Heskel M, Spivack JH, Feferman Y, Ang C, Gany F. Sarpel U, et al. J Health Care Poor Underserved. 2018;29(3):1123-1134. doi: 10.1353/hpu.2018.0083. J Health Care Poor Underserved. 2018. PMID: 30122687 Free PMC article.
MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway.
Rao M, Chen D, Zhan P, Jiang J. Rao M, et al. Biol Direct. 2019 May 3;14(1):9. doi: 10.1186/s13062-019-0241-1. Biol Direct. 2019. PMID: 31053086 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information